MMJ PhytoTech Limited (ASX:MMJ) (OTCMKTS:MMJJF) ("MMJ") is pleased to attach a release from MediPharm Labs Inc ("MediPharm Labs") (TSX-V: LABS) announcing that it has entered into a Cannabis Concentrate Program Agreement with Emerald Health Therapeutics Inc ("Emerald") (CVE:EMH).

MMJ has CAD$5 million of equity invested in MediPharm Labs with 5.88 million shares (CAD$0.85 cost per share) and 2.94 million warrants (exercisable at CAD$1.20 per share by October 2020).

To view the release, please visit:
http://abnnewswire.net/lnk/F8RY7W5L


About MMJ PhytoTech Ltd

MMJ PhytoTech Limited (ASX:MMJ) is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: http://www.mmjphytotech.com.au/investors/

      

Contact

Investor and Media Enquiries:
Jason Conroy
Chief Executive Officer
T: +61-2-8098-0819
E: info@mmjgh.com.au



Link: MediPharm Labs enters contract with Emerald



Related Companies

MMJ PhytoTech Ltd
  

Emerald Health Therapeutics Inc


Related Industry Topics:
Food & Beverage Medical Equipment Drugs & OTC Ag Biotechnology Consumers General Health & Pharm General